Professional Documents
Culture Documents
INNATE IMMUNITY
MEMORY IMMUNITY
Potential conflicts of interest: A.M.A. has received honoraria from Merck, the
manufacturer of the varicella vaccine.
Financial support: supplement sponsorship is detailed in the Acknowledgments.
Reprints or correspondence: Dr. Ann M. Arvin, G312, Dept. of Pediatrics,
Stanford University School of Medicine, 300 Pasteur Dr., Stanford, CA 94305
(aarvin@stanford.edu).
The Journal of Infectious Diseases 2008; 197:S5860
2008 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2008/19705S2-0006$15.00
DOI: 10.1086/522123
The memory immune response that follows the resolution of naturally acquired primary VZV infection is
characterized by the persistence of VZV IgG antibodies
and, in most cases, VZV IgA antibodies, as well as VZVspecific CD4 and CD8 T cells [1]. VZV-specific IgG
antibodies have been shown to bind many VZV proteins and function to mediate neutralization and antibody-dependent cytotoxicity. The overall frequency of
Under conditions of naturally acquired primary varicella-zoster virus (VZV) infection, the first response of
the naive host is mediated by the innate immune system
through antiviral cytokines and the activation of NK
cells [1]. These responses are likely to be important for
the initial control of VZV at mucosal sites of inoculation and to trigger the induction and amplification
of adaptive, VZV-specific immunity. NK cells can lyse
VZV-infected targets [2], and activated NK cells are a
major source of interferon (IFN)g production, which
enhances the clonal expansion of antigen-specific T
cells. IFN-a inhibits VZV replication in vitro, and treatment with exogenous type I IFN-a reduced the severity
of varicella in immunocompromised children with varicella [3]. In addition, VZV replication in skin is associated with extensive production of IFN-a by adjacent uninfected epidermal cells in the SCIDhu model
of VZV pathogenesis; blocking this IFN-a response
caused a dramatic increase in VZV spread in skin [4].
Innate mechanisms of immune control have the capacity to maintain the host-virus equilibrium, despite
the VZV immune evasion strategies that inhibit both
class I and class II major histocompatibility complex
(MHC) mechanisms for antigen presentation to T cells
while the virus is being transferred to skin and in early
stages of cutaneous infection [46]. These strategies
VACCINE IMMUNITY
According to current models, memory antiviral immunity is
thought to be a consequence of the magnitude of the expansion
of effector cell populations elicited by primary exposure to the
pathogen [22] (figure 1). Memory immune responses are lower
when the initial immunologic burst is limited, because virusspecific effector cell populations are normally regulated to decrease during the weeks to months after primary sensitization
and expansion. The antigenic signal appears to be the most
important factor in driving the expansion and, therefore, is
expected to have direct consequences for the immunologic set
point of the memory immune response. VZV immune responses peak within a few weeks after naturally acquired infection and decline to a persistent memory response with the
characteristics described earlier. The capacity of the live attenuated varicella vaccine to elicit VZV IgG and T cell immunity
Figure 1. Importance of the initial burst of the adaptive host response for establishing long-term antiviral immunity. VZV, varicella-zoster
virus.
Acknowledgments
Supplement sponsorship. This article was published as part of a supplement entitled Varicella Vaccine in the United States: A Decade of Prevention and the Way Forward, sponsored by the Research Foundation for
Microbial Diseases of Osaka University, GlaxoSmithKline Biologicals, the
Sabin Vaccine Institute, the Centers for Disease Control and Prevention,
and the March of Dimes.
References
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
1. Arvin AM. Varicella-zoster virus. In: Knipe DM, Howley P, eds. Fields
virology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:
273168.
2. Ihara T, Kato T, Torigoe S, et al. Antibody response determined with
antibody-dependent cell-mediated cytotoxicity (ADCC), neutralizing
antibody, and varicella skin test in children with natural varicella and
after varicella immunization. Acta Paediatr Jpn 1991; 33:439.
3. Arvin AM, Kushner JH, Feldman S, et al. Human leukocyte interferon
for treatment of varicella in children with cancer. N Engl J Med
1982; 306:7617.
4. Ku C-C, Zerboni L, Besser J, Ito H, Arvin AM. Varicella-zoster virus
transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-a. J Exp Med 2004; 200:91725.
5. Abendroth A, Slobedman B, Eunice L, Mellins E, Wallace M, Arvin
AM. Modulation of MHC class II protein expression by varicella zoster
virus. J Virol 2000; 74:19007.
6. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. Varicellazoster virus retains major histocompatibility complex class I proteins
in the Golgi compartment of infected cells. J Virol 2001; 75:487888.
7. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. Early
immune response in healthy and immunocompromised subjects with
primary varicella-zoster virus infection. J Infect Dis 1986; 154:4229.
8. Arvin A. Varicella-zoster virus: virologic and immunologic aspects of
persistent infection. In: Ahmed R, Chen I, eds. Persistent viral infections. New York: John Wiley & Sons, 1998:183208.
9. Gershon AA, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 1997; 176:1496500.
10. Diaz PS, Smith S, Hunter E, Arvin AM. T lymphocyte cytotoxicity
with natural varicella-zoster virus infection and after immunization
with live attenuated varicella vaccine. J Immun 1989; 142:63641.
11. Arvin AM, Sharp M, Smith S, et al. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I
by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J
Immunol 1991; 146:25764.
12. Webster AD, Spickett GP, Thomson BJ, Farrant J. Viruses and antibody
deficiency syndromes. Immunol Invest 1988; 17:93105.
13. Hayward AR, Pontesilli O, Herberger M, Laszlo M, Levin M. Specific
lysis of varicella zoster virus-infected B lymphoblasts by human T cells.
J Virol 1986; 58:17984.
14. Jenkins DE, Redman RL, Lam EM, Liu C, Lin I, Arvin AM. Interleukin